# University licences with royalties indexed to benefit and global access

Source: https://onco.cc/ideas/idea-fund-global-access-licensing-royalties/  
OnCo record `idea-fund-global-access-licensing-royalties` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

When universities license cancer discoveries to companies, the contract would reward companies that price fairly and sell in poor countries, and penalise those that do not, using the royalty rate as the lever.

## Summary

Technology transfer offices adopt a standard licence for oncology inventions in which the royalty rate steps down when the licensee meets access conditions (registration and tiered pricing in a list of low- and middle-income countries within two years of first approval, non-exclusive licensing to the Medicines Patent Pool for those markets) and steps up if the launch price exceeds a value-based reference. Since a large share of first-in-class cancer drugs originate in academic labs (including the checkpoint inhibitors and CAR-T), universities collectively hold leverage they rarely use. Universities Allied for Essential Medicines has drafted model clauses; the change is to make them the default for cancer.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: If twenty leading research universities adopt indexed licences, oncology drugs derived from their patents are registered in at least twice as many low- and middle-income countries within three years of first approval as comparable drugs, with no measurable fall in licensing deal flow.
- Rationale: Yale's licence for stavudine and subsequent global-access licensing (for example Medicines Patent Pool licences for hepatitis C and HIV drugs) show that upstream terms can determine downstream access; the royalty step is a low-cost, self-enforcing mechanism.
- Proposed test: A consortium of universities adopts the licence for all new oncology deals; compare registration breadth and pricing of resulting products with a matched historical cohort after five years.
- Maturity: speculative
- Actor: policy

## Sources

- Universities Allied for Essential Medicines: https://www.uaem.org/
- Medicines Patent Pool: https://medicinespatentpool.org/

## Connected records

- ideas: [A Health Impact Fund pilot that pays for measured health gain instead of price](https://onco.cc/ideas/idea-fund-health-impact-fund-oncology/), [An oncology patent pool for combination trials across companies](https://onco.cc/ideas/idea-fund-combination-patent-pool/), [Transferable priority vouchers for first-in-class drugs, with price conditions](https://onco.cc/ideas/idea-fund-conditional-transferable-voucher/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-global-access-licensing-royalties.json